ecogacrinnews2

December 20, 2022

A General Session to Remember: NCI Director Monica Bertagnolli Delivers First Public Speech, ECOG-ACRIN Honors Two Esteemed Colleagues

Some of the most memorable moments of the 10th Anniversary General Session featured three individuals who have been key participants and collaborators in ECOG-ACRIN’s research over the years
December 20, 2022

Aurora NCORP Pilots Natural Language Processing Tool to Find Patients with Pancreatic Cysts for EA2185

Funding and support are now available to sites to implement natural language processing for recruitment of patients to study EA2185
December 20, 2022

Trial Spotlight: Robert Ferris on the EA3132 Trial for Patients with Head and Neck Cancer

This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck
October 13, 2022

Charmaine Green on Cultivating a Career in Health Care Administration

Health care administrator Charmaine Green shares her experience supporting cancer clinical trials and discusses how her role has evolved over the years
October 13, 2022

Meet the 2022 Young Investigator Symposium Presenters

Eight early-career investigators will present their work; two will be selected to receive awards of distinction
October 13, 2022

Trial Spotlight: Yishai Ofran on the EA9181 Study for Acute Lymphoblastic Leukemia

This phase 3 study aims to explore whether treatment with a TKI plus blinatumomab may be superior to the usual treatment approach for acute lymphoblastic leukemia
October 13, 2022

Institution Spotlight: Michigan Cancer Research Consortium NCORP

A Standing Main Member of ECOG-ACRIN since 1983
October 13, 2022

News in Brief, October 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 16, 2022

NCI-MATCH precision medicine trial leads to FDA drug approval for BRAF V600E-mutated tumors

Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
August 16, 2022

Trial Spotlight: Neha Vapiwala on the EA8191/INDICATE Study for Prostate Cancer

This phase III study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
August 16, 2022

News in Brief, August 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022

Trial Spotlight: Nadine Tung on the EA1181/CompassHER2 pCR Trial for HER2-Positive Breast Cancer

This study aims to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with pathologic complete response (pCR) after 12 weeks of pre-operative treatment